The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| UNCY | +25.43% | N/A | N/A | -90% |
| S&P | +13.66% | +87.02% | +13.34% | +53% |
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.15M | -20.3% |
| Market Cap | $77.01M | 92.9% |
| Market Cap / Employee | $3.50M | 0.0% |
| Employees | 22 | 57.1% |
| Net Income | -$6.01M | -46.8% |
| EBITDA | -$7.19M | -17.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $42.70M | 32.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.27M | -51.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -75.06% | 24.7% |
| Return On Invested Capital | 865.35% | -146.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.96M | 35.7% |
| Operating Free Cash Flow | -$5.96M | 35.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 12.17 | 6.11 | 5.07 | 3.75 | 161.29% |
| Price to Sales | 44.68 | - | |||
| Price to Tangible Book Value | 27.91 | 88.07 | 5.07 | 3.75 | -131.28% |
| Enterprise Value to EBITDA | -7.13 | -6.62 | -5.39 | -5.05 | 552.98% |
| Return on Equity | -185.2% | -2355.3% | -3987.1% | -102.5% | - |
| Total Debt | $0.77M | $0.55M | $0.41M | $0.27M | -67.16% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
